When was Xaira founded?

Xaira was founded in 2023 and become a unicorn in its 1st funding round in 2024.

Where is Xaira located?

Xaira is headquartered in San Francisco, United States.

Who is the current CEO of Xaira?

Marc Tessier Lavigne of Xaira. They have also founded 1 company.

How many employees does Xaira have?

As of Jun 30, 2026, the latest employee count at Xaira is 212.

Is Xaira a funded company?

Xaira is a funded company, having raised a total of $1B in its 1st and only funding round, a Series D round on Apr 23, 2024.

How much is Xaira worth?

The latest valuation of Xaira is $4B as of Apr 23, 2024.

When was the latest funding round of Xaira?

Xaira's latest funding was a $1B Series D round on Apr 23, 2024, with participation from 13 investors.

Is Xaira a Life Sciences Tech company?

The primary sector of Xaira is Life Sciences Tech.

Where does Xaira rank among its competitors?

Xaira ranks 5th amongst 191 active competitors, of which 70 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Isomorphic Labs, which secured $2.1B in May, 2026.

Who are the top competitors of Xaira?

Xaira's top competitors include Schrodinger, Recursion Pharmaceuticals and XtalPi. Among them, Isomorphic Labs secured the most recent funding round in May, 2026.

Xaira - 2026 Company Profile, Team, Funding & Competitors

Sectors and market segments that Xaira operate in

Xaira serves in the HealthTech, Life Sciences market segments.The primary business model of Xaira are:

Company Details

AI-enabled platform for drug discovery and development. It combine robust product development, biological and clinical data generation, and AI methods research, both translational and fundamental for drug discovery and development process.

Website: www.xaira.com/
Email ID: *****@xaira.com

Key Metrics

Founded Year

2023

Location

San Francisco, United States

Stage

Series D

Total Funding

$1B in 1 round

Latest Funding Round

Series D, Apr 23, 2024, $1B

Post Money Valuation

$4B as on Apr 23, 2024

Investors

Arch Venture Partners & 12 more

Ranked

5^th among 191 active competitors

Employee Count

212 as on Jun 30, 2026

Similar Companies

Schrodinger & 220 more

View Xaira's full profile

Xaira has raised a total funding of $1B over 1 round. Its latest funding round was a Series D round on Apr 23, 2024 for $1B. 13 investors participated in its latest round. Xaira has 13 institutional investors.

Here is the list of recent funding rounds of Xaira:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 23, 2024	$1B	Series D	$4B	-	Arch Venture Partners, Foresite Labs	F-Prime Capital, New Enterprise Associates, Sequoia Capital, Lux Capital, Lightspeed Venture Partners, Menlo Ventures, Two Sigma Ventures, PICI, Byers Capital, SV Angel, Risk and Return

Access funding benchmarks and valuations. Sign up today!

View details of Xaira's funding rounds and investors

The founders of Xaira are Vik Bajaj, Marc Tessier Lavigne, David Baker, Robert Nelsen and Hetu K. Marc Tessier Lavigne is the CEO of Xaira.

Here are the details of Xaira's key team members:

Vik Bajaj: Co-Founder of Xaira and founder of 1 other company.
Contact Info: 1 email address
Marc Tessier Lavigne: Co-Founder & CEO of Xaira.
David Baker: Co-Founder of Xaira.
Robert Nelsen: Co-Founder & Director of Xaira.
Hetu K: Co-Founder & CTO of Xaira.
Contact Info: 1 email address

View details of Xaira's Founder profiles and Board Members

Xaira's employee count trend

Xaira has 212 employees as of Jun 26. Here is Xaira's employee count trend over the years:

Uncover Xaira's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Xaira include Schrodinger, Recursion Pharmaceuticals and XtalPi. Here is the list of Top 10 competitors of Xaira, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Schrodinger 1990, New York City (United States), Acquired	Provider of a web-based simulation and modelling tool	$162M	Gates, WuXi AppTec & 16 others	74/100
2nd	Recursion Pharmaceuticals 2013, New York (United States), Public	AI-enabled drug discovery and development platform for novel therapeutics	$452M	Baillie Gifford, Felicis Ventures & 47 others	72/100
3rd	XtalPi 2014, Cambridge (United States), Public	AI-based drug research and development company	$785M	Orbimed, SoftBank Vision Fund & 25 others	67/100
4th	Isomorphic Labs 2021, London (United Kingdom), Series B	Digital platform focused on revolutionizing drug discovery using AI	$2.7B	Thrive Capital, CapitalG & 6 others	64/100
5th	Xaira 2023, San Francisco (United States), Series D	AI-enabled platform for drug discovery and development	$1B	Menlo Ventures, Lightspeed Venture Partners ... & 11 others	63/100
6th	Valo Health 2019, Boston (United States), Series B	AI-powered platform for drug discovery and development	$450M	PSP Investments, Koch Disruptive Technologies ... & 7 others	63/100
7th	Tandem AI 2021, New York (United States), Series A	AI-based drug discovery tool for researchers	$82M	Orbimed, Chengwei Capital & 4 others	62/100
8th	In Silico 2014, Cambridge (United States), Public	AI-enabled bioinformatics platform for drug discovery and biomarker development	$510M	Qiming Venture Partners, Prosperity7 Ventures ... & 36 others	62/100
9th	Causaly 2018, London (United Kingdom), Series B	Provider of an AI platform for life sciences and biomedical research	$93M	Index Ventures, Iconiq Capital & 14 others	62/100
10th	Healx 2014, Cambridge (United Kingdom), Series C	Provider of AI-powered drug discovery solutions for rare diseases	$115M	Atomico, Amadeus Capital & 19 others	62/100